Increasing evidence suggests that RBP4 induces insulin resistance (IR) (9, 10) and is closely associated with diabetes mellitus (DM) (11, 12), obesity (13), metabolic syndrome (MS) (14, 15), hyperuricaemia (HUA) (16, 17), non-alcoholic fatty liver disease (NAFLD) (18, 19), hypertension (HTN) (20, 21), and cardiovascular diseases (CAD) (22). This evidence concerns the gene RBP4 and metabolic dysfunction-associated steatotic liver disease.